Novartis AG exits India: ChrysCapital buys 70.68% stake, takes control

Promoter holding below 50%Ownership Changes View source PDF Explain this filing

NOVARTIND · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.0%Reaction day

₹1600.00

prior close

₹1610.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.6%-0.4% vs market

Pharmaceuticals peers, median of 162sector-0.7%-0.3% vs sector

On the reaction day the stock moved 0.4 pts less than Nifty Microcap 250 and 0.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.2

10m

-0.2

15m

-0.5

30m

-0.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.0-0.6-0.4-0.7-0.3

Next day

-2.4+0.5-2.9-0.5-1.9

+2.8+1.9+0.9+0.2+2.6

+1.8+2.3-0.5+0.1+1.7

+2.3+3.6-1.4+0.5+1.8

-0.1+4.0-4.1+0.7-0.8

+0.2+4.0-3.7+1.4-1.2

15d

-7.3+4.9-12.2+0.4-7.7

-1.6+5.9-7.5+1.7-3.3

+19.7+4.8+14.9+2.7+17.0

+7.8pendingpending-3.1+10.9

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 162Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Novartis AG completed the sale of its entire 70.68% stake (1.74 crore equity shares) in Novartis India to ChrysCapital entities (WaveRise Investments, ChrysCapital Fund X, Two Infinity Partners) on July 29, 2026. WaveRise and Fund X have acquired control of the company. NAG has been reclassified from promoter to public category. A separate open offer for 26% from public shareholders was also conducted under takeover rules.

Likely market impact

Major ownership change. The stock is now a ChrysCapital portfolio company, which may reshape business strategy, valuation, and long-term direction.